Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · October 21, 2024

Outcomes of Datopotamab Deruxtecan vs Chemotherapy in Previously Treated Patients With Inoperable/Metastatic HR+/HER2− Breast Cancer

Journal of Clinical Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Clinical Oncology
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01
J. Clin. Oncol 2024 Sep 12;[EPub Ahead of Print], A Bardia, K Jhaveri, SA Im, S Pernas, M De Laurentiis, S Wang, N Martínez Jañez, G Borges, DW Cescon, M Hattori, YS Lu, E Hamilton, Q Zhang, J Tsurutani, K Kalinsky, PE Rubini Liedke, L Xu, RM Fairhurst, S Khan, N Denduluri, HS Rugo, B Xu, B Pistilli

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading